Drugs /

camrelizumab

Back to Drugs List
Associated Genetic Biomarkers

Overview

Trade Name(s):
Airuika (Tm)
NCI Definition [1]:
A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody SHR-1210 binds to and blocks the binding of PD-1, expressed on activated T-lymphocytes, B-cells and natural killer (NK) cells, to its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen presenting cells (APCs). This prevents the activation of PD-1 and its downstream signaling pathways. This restores immune function through the activation of cytotoxic T-lymphocytes (CTLs) and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.

Clinical Trials

View Clinical Trials for camrelizumab

Camrelizumab has been investigated in 13 clinical trials, of which 11 are open and 2 are closed. Of the trials investigating camrelizumab, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 5 are phase 2 (4 open), and 4 are phase 3 (3 open).

EGFR A763_Y764insFQEA, EGFR Exon 19 Deletion, and EGFR Exon 19 Insertion are the most frequent biomarker inclusion criteria for camrelizumab clinical trials.

Non-small cell lung carcinoma, adenocarcinoma of the gastroesophageal junction, and gastric adenocarcinoma are the most common diseases being investigated in camrelizumab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Camrelizumab
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Camrelizumab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating camrelizumab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
AiRuiKa (TM), shr 1210, shr1210, shr-1210, hr-301210
Drug Categories [2]:
Anti-PD-1 antibodies
Drug Target(s) [2]:
PDCD1
NCIT ID [1]:
C123816

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.